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Table1: Prevalence of radiographic OA of the knee, as a function of age and
gender
Gender, age
range
n
(knees)
Radiographic
osteoarthritis(%)
Grade 3 or4
changes(%)
Female 800 51.7* 19,4*
w49 84 10.7 0.0
50–59 82 22.0 1.2
60–69 218 43.6* 10.6*
70–79 302 67.9* 26.5*
80w 114 83.3* 47.4*
Male 626 31.3* 7.5*
w49 50 0.0 0.0
50–59 48 12.5 4.2
60–69 162 16.7* 3.7*
70–79 256 38,3* 9.0*
80w 110 59.1* 14.5*
*P < 0.001 for differences in prevalence between males and females for each par-
ticular age range, and in total.
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PREVALENCE OF KNEE OSTEOARTHRITIS AND IMPACT OF
HYALURONIC ACID TREATMENT ON PAIN AND MOBILITY IN A
CANADIAN REAL-WORLD POPULATION
R.J. Petrella y, D.P. Gill y, C. Wakeford z. yU Western Ontario, London, ON,
Canada; z Sanoﬁ Canada, Laval, QC, Canada
Purpose: Given the paucity of large, real-world datasets for the inves-
tigation of knee osteoarthritis, the purpose of this study was to identify
and describe the treatment patterns and effects of intra-articular hya-
luronic acid (HA) on knee osteoarthritis pain and mobility in a large,
Canadian, real-world population.
Methods: This is an observational, retrospective cohort of patients 18
years and older who, between June 1, 1999 and December 31, 2012 had:
1) a diagnosis of knee osteoarthritis identiﬁed by ICD9-10 and/or text
coding; 2) received at least 1 treatment cycle with intra-articular HA
and; 3) complete pain andmobility data [i.e., pain Visual Analogue Scale
(VAS) and 6-minute walk test measures] for each treatment cycle. Data
came from the Southwestern Ontario (SWO) database, which is a rep-
resentative primary care, researchable database of over 325,000 unique
patient records in Ontario, Canada. The SWO has compiled data con-
tinuously beginning from 1999 until present. This database has shown
similar prevalence to the Canadian population for several chronic dis-
eases and includes demographic, biometric, laboratory, diagnostic and
health resource measures as collected in a primary care setting. Treat-
ments were provided as per usual care of the provider. In addition to
demographic data, pain [VAS (0–10 cm) pre and post treatment at rest],
and mobility (6-minute walk test in meters) were examined in this
study. Differences within and between treatments were compared
using paired and independent samples t-tests.
Results: Among 325,000 patients in the SWO database, 20,187 patients
had a diagnosis of osteoarthritis of the knee (6.2% prevalence) with
6,618 receiving at least 1 treatment cycle of any intra-articular HA
product (33% prevalence). Treatments included Hylan G-F 20 (Synvisc,
Genzyme Biosurgery) (43%) and others (57%). Mean age (SD) was 57 (11)
years at diagnosis and 71 (18) years at the time of ﬁrst HA treatment. A
high proportion of patients were male (61%), overweight or obese
according to standard body mass index cut-points (>80%), had co-
morbidities [i.e., diabetes (10%); hypertension (66%); and dyslipidemia
(13%)], and were predominantly grade 2–3 on radiographic examina-
tion (>75%). On average, patients received between 3 and 8 HA treat-
ment cycles. Among all patients, VAS at rest (weight-bearing)
signiﬁcantly improved following treatment (7.2 cm to 4.1 cm, p < 0.05).
Mobility (6-minute walk test) also improved post-treatment (321 m to
423m, p< 0.05). Comparing Hylan G-F 20 with all other HA treatments,
post-treatment VAS at rest (weight-bearing) was signiﬁcantly lower
(3.3 cm vs 4.1 cm, p < 0.05) and distance walked (6-minute walk test)
was signiﬁcantly greater (463 m vs 399 m, p < 0.05).
Conclusions: Osteoarthritis of the knee is a signiﬁcant problem in
primary care affecting pain and mobility. In this Canadian real-worlddatabase, initial analyses indicated that treatment with intra-articular
HA may improve pain and mobility. This real-world database may be
used as a potential resource for further examination of the effectiveness
of HA for reducing pain and improving mobility in knee osteoarthritis.
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MULTIPLE SYMPTOMATIC JOINTS ARE ASSOCIATED WITH
INCREASED HEALTH RESOURCE UTILIZATION AMONG PATIENTS
UNDERGOING TOTAL KNEE ARTHROPLASTY FOR OSTEOARTHRITIS
M.G. Zywiel, R. Chaudhary, Y.R. Rampersaud, R. Gandhi,
N.N. Mahomed, A.V. Perruccio. Arthritis Program, University Health
Network; Univ. of Toronto, Toronto, ON, Canada
Purpose: Hospitals and surgeons continue to be under increased cost
pressure with respect to total knee arthroplasty (TKA), with increasing
material costs and decreasing reimbursements. Recent evidence sug-
gests that multiple symptomatic joint involvement in patients with
osteoarthritis (OA) may be associated with poorer patient reported
outcomes when compared to those who have a single symptomatic
joint. However, it remains unclear whether this is associated with any
differences in in-hospital resource utilization. The purpose of the
present study was to evaluate whether the presence of multiple
symptomatic joints is associated with differences in length of stay,
discharge disposition, American Society of Anesthesiologists (ASA)
class, post-operative adverse event rates, or episode of care costs from
the hospital perspective in patients undergoing primary TKA for OA.
Methods: All patients who underwent primary TKA for OA at a single
institution between April 2011 and October 2012 were reviewed.
Patients with a history of rheumatoid arthritis or inﬂammatory
arthropathy were excluded, as were patients undergoing bilateral
procedures. Prospectively collected demographic and clinical data,
including number and location of symptomatic joints, as well as ASA
class and discharge disposition were extracted. Data were liked with a
hospital administrative costing database. Post-operative adverse event
rates were tracked prospectively and included in the analysis. Patients
were grouped into three categories based on joint involvement: 1)
symptoms in the operated joint only, 2) symptoms in a total of 2–4
joints, and 3) ﬁve or more symptomatic joints. A total of 245 patients
were included, with 35, 99, and 111 in each group, respectively.
Results: Signiﬁcant differences were seen in mean length-of-stay
between patient groups (3.74, 3.96 and 4.19 days respectively; p ¼
0.042), with longer time to discharge in patients with multiple joint
involvement. These differences were maintained when patients dis-
charged to rehabilitation facilities were excluded (p ¼ 0.015), and were
not explained by differences in mean patient age (64, 65 and 65 years of
age respectively; p ¼ 0.925), the need for stair training before discharge
home (93%, 93% and 86% of patients; p ¼ 0.290), or in-hospital adverse
event rates (p ¼ 0.315). No signiﬁcant differences in the proportion of
patients discharged to home were identiﬁed based on degree of multi-
joint involvement (83%, 81% and 76% respectively; p ¼ 0.540). Multiple
joint involvement was positively associated with increasing mean ASA
class (2.26, 2.33, 2.61 respectively; p < 0.001), but was not correlated
with the incidence of in-hospital adverse events (r ¼ 0.012). Increasing
joint involvement was associated with signiﬁcantly greater mean epi-
sode of care costs from a hospital perspective (p ¼ 0.024), and this
relationship was maintained when the analysis was limited to patients
who were discharged home (p ¼ 0.011). Patients with involvement of 5
or more joints accrued an incremental 9% cost burden to the hospital
when compared to those with single joint disease ($10,251 vs $9,379
per patient). Assuming a similar nation-wide prevalence of multiple
joint symptoms, this represents a total incremental cost burden of
$19,500,000 per year to the Canadian health care system based on
2008/2009 nationwide case volumes.
Conclusions: The results of the present study provide evidence of dif-
ferences in in-hospital health resource utilization following TKA for OA
between patients who have multiple symptomatic joints when com-
pared to those with a minimal number of symptomatic joints. These
patients appear to have a greater severity of systemic disease as evi-
denced by greater mean ASA scores, although this did not translate into
